A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

To join this study, participants must be at least 18 years old. You would need to have B-cell non-Hodgkin lymphoma that has either come back after previous treatments or has not responded to at least two previous types of treatment. For certain parts of the study, you might only need to have had one previous treatment.

Your doctor will need to confirm that your cancer can be measured. You also need to be well enough to take part, with decent organ function, and generally be expected to live for at least another 24 weeks. The research team will also need a small piece of your tumour tissue that has been preserved.

Both men and women can participate. If you are a woman who could become pregnant, or a man with a female partner who could become pregnant, you will need to agree to use effective contraception during the study and for some time after the last dose of treatment. This is to prevent pregnancy and ensure the safety of any potential offspring.

If you decide to join this study, you will receive a combination of medicines being tested. The specific drugs and how often you receive them will depend on which group you are in. You will have regular visits to the hospital or clinic for blood tests, physical examinations, and other checks to monitor your health and how the treatment is working. Doctors will closely watch for any side effects and adjust your care as needed.

The study involves two main parts: a 'dose-finding' part where different doses are tried, and an 'expansion' part where the best dose is given to more people. The total duration of your participation will vary, but you will be monitored throughout your treatment and likely for some time afterwards. The study team will explain all the details of your specific treatment plan and visit schedule before you agree to take part.